MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus

Por Karolina, Dwi Setyowati, Armugam, Arunmozhiarasi, Tavintharan, Subramaniam, Wong, Michael T. K., Lim, Su Chi, Sum, Chee Fang, Jeyaseelan, Kandiah
Publicado em 2011

Correction: MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus

Por Karolina, Dwi Setyowati, Armugam, Arunmozhiarasi, Tavintharan, Subramaniam, Wong, Michael T. K., Lim, Su Chi, Sum, Chee Fang, Jeyaseelan, Kandiah
Publicado em 2011

Inhibition of bladder cancer development by allyl isothiocyanate

Por Bhattacharya, Arup, Tang, Li, Li, Yun, Geng, Feng, Paonessa, Joseph D., Chen, Shang Chiung, Wong, Michael K.K., Zhang, Yuesheng
Publicado em 2010

A2A adenosine receptor protects tumors from antitumor T cells

Por Ohta, Akio, Gorelik, Elieser, Prasad, Simon J., Ronchese, Franca, Lukashev, Dmitriy, Wong, Michael K. K., Huang, Xiaojun, Caldwell, Sheila, Liu, Kebin, Smith, Patrick, Chen, Jiang-Fan, Jackson, Edwin K., Apasov, Sergey, Abrams, Scott, Sitkovsky, Michail
Publicado em 2006

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Por Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Publicado em 2014

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

Por Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Publicado no J Immunother Cancer (2017)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Por Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Publicado no Cancer Immunol Immunother (2016)

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma

Por McDermott, David F., Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A., Clark, Joseph I., Sosman, Jeffrey A., Dutcher, Janice P., Logan, Theodore F., Curti, Brendan D., Ernstoff, Marc S., Appleman, Leonard, Wong, Michael K.K., Khushalani, Nikhil I., Oleksowicz, Leslie, Vaishampayan, Ulka N., Mier, James W., Panka, David J., Bhatt, Rupal S., Bailey, Alexandra S., Leibovich, Bradley C., Kwon, Eugene D., Kabbinavar, Fairooz F., Belldegrun, Arie S., Figlin, Robert A., Pantuck, Allan J., Regan, Meredith M., Atkins, Michael B.
Publicado no Clin Cancer Res (2014)